(Q38855728)

7 September 2017

1 reference

title

Old and new applications of non-anticoagulant heparin (English)

1 reference

7 September 2017

1 reference

1 reference

Giuseppe Cassinelli

1

1 reference

PubMed ID

27264866

7 September 2017

Annamaria Naggi

series ordinal

2

1 reference

PubMed ID

27264866

7 September 2017

language of work or name

English

0 references

publication date

1 June 2016

1 reference

International Journal of Cardiology

7 September 2017

1 reference

7 September 2017

212 Suppl 1

1 reference

7 September 2017

S14-21

1 reference

Re-visiting the structure of heparin

7 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparin-protein interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Selectins facilitate carcinoma metastasis and heparin can prevent them.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

A systematic review of heparin to treat burn injury

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Anti-proliferative effects of O-acyl-low-molecular-weight heparin derivatives on bovine pulmonary artery smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

The antioxidant activity of heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Inhibition of the human leukocyte endopeptidases elastase and cathepsin G and of porcine pancreatic elastase by N-oleoyl derivatives of heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Effects of heparin and related molecules upon neutrophil aggregation and elastase release in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparin derivatives for the targeting of multiple activities in the inflammatory response.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Inhibition of leucocyte elastase by heparin and its derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparanases and tumor metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Involvement of heparanase in atherosclerosis and other vessel wall pathologies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparanase upregulation by colonic epithelium in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparin/heparan sulphate interactions with complement--a possible target for reduction of renal function loss?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Therapeutic use of heparin beyond anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Inhibition of P-glycoprotein-mediated multidrug resistance by unfractionated heparin: a new potential chemosensitizer for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Antimetastatic activities of heparins and modified heparins. Experimental evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparins and cancer survival: where do we stand?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Optimization of small-cell lung cancer chemotherapy with heparin: a comprehensive retrospective study of 239 patients treated in a single specialized center.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Release of sequestered malaria parasites upon injection of a glycosaminoglycan

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Neutrophils in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Response to heparin in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Pharmacological approaches to discovery and development of new mucolytic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Treatment of radiation-induced nervous system injury with heparin and warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Rheumatoid arthritis and heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Low-dose heparin for severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Topically applied heparins for the treatment of vascular disorders : a comprehensive review

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Inhibitory effect of heparin on herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Correlation of sulfate content and degree of carboxylation of heparin and related glycosaminoglycans with anticomplement activity. Relationships to the anticoagulant and platelet-aggregating activities

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Endogenous heparin activity deficiency: the 'missing link' in atherogenesis?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Sulfated polysaccharides prevent human leukocyte elastase-induced acute lung injury and emphysema in hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

New insights into the inhibition of human neutrophil elastase by heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Syndecans in inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparin oligosaccharides that pass the blood-brain barrier inhibit beta-amyloid precursor protein secretion and heparin binding to beta-amyloid peptide.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Inhibition of amyloidosis using low-molecular-weight heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

An overview of potential applications of heparin in vitreoretinal surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Clinical management of proliferative vitreoretinopathy: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

The effect of IVX-0142, a heparin-derived hypersulfated disaccharide, on the allergic airway responses in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Influence of Low Molecular Mass Heparin on the Kinetics of Neutrophil Elastase Inhibition by Mucus Proteinase Inhibitor(*)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Low molecular weight heparin stimulates megakaryocytopoiesis in bone-marrow transplantation patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Assays and reference materials for current and future applications of heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Molecular modeling of protein-glycosaminoglycan interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Order out of complexity--protein structures that interact with heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Semi-synthetic heparin derivatives: chemical modifications of heparin beyond chain length, sulfate substitution pattern and N-sulfo/N-acetyl groups

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Bioactivity screening of partially desulfated low-molecular-weight heparins: a structure/activity relationship study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparin derivatives as inhibitors of BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor Xa and other proteases.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Disruption of rosetting in Plasmodium falciparum malaria with chemically modified heparin and low molecular weight derivatives possessing reduced anticoagulant and other serine protease inhibition activities.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Structure and biological interactions of heparin and heparan sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparin binding to human plasma low-density lipoproteins: dependence on heparin sulfation degree and chain length

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Antitumor effect of butanoylated heparin with low anticoagulant activity on lung cancer growth in mice and rats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Glycol-cleavage oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Further evidence that periodate cleavage of heparin occurs primarily through the antithrombin binding site

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparanase stimulates chondrogenesis and is up-regulated in human ectopic cartilage: a mechanism possibly involved in hereditary multiple exostoses

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Pre-clinical and clinical significance of heparanase in Ewing's sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Vasoflux, a new anticoagulant with a novel mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Low molecular weight heparin stimulates myometrial contractility and cervical remodeling in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparins designed to specifically inhibit platelet interactions with von Willebrand factor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Blocking of integrin-mediated human MV3 melanoma cell binding by commercial and modified heparins.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Hepcidin antagonists for potential treatments of disorders with hepcidin excess

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Novel sulfated polysaccharides: dissociation of anti-human immunodeficiency virus activity from antithrombin activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Molecular-weight-dependent effects of nonanticoagulant heparins on allergic airway responses

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Role of endothelial heparanase in delayed-type hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Undersulfated and glycol-split heparins endowed with antiangiogenic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Anti-HIV type 1 properties of chemically modified heparins with diminished anticoagulant activity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Chemoenzymatic synthesis of heparan sulfate and heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Orally active desulfated low molecular weight heparin and deoxycholic acid conjugate, 6ODS-LHbD, suppresses neovascularization and bone destruction in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Recent advances in search of oral heparin therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

Oral heparin: status review

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2816%2912004-2

7 January 2021

10.1016/S0167-5273(16)12004-2

Identifiers

DOI

1 reference

7 September 2017

1 reference

PubMed ID

27264866